277 related articles for article (PubMed ID: 32770088)
1. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network.
Gu X; Tohme R; Tomlinson B; Sakre N; Hasipek M; Durkin L; Schuerger C; Grabowski D; Zidan AM; Radivoyevitch T; Hong C; Carraway H; Hamilton B; Sobecks R; Patel B; Jha BK; Hsi ED; Maciejewski J; Saunthararajah Y
Leukemia; 2021 Apr; 35(4):1023-1036. PubMed ID: 32770088
[TBL] [Abstract][Full Text] [Related]
2. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
Hill B; Jagadeesh D; Pohlman B; Dean R; Parameswaran N; Chen J; Radivoyevitch T; Morrison A; Fada S; Dever M; Robinson S; Lindner D; Smith M; Saunthararajah Y
Semin Hematol; 2021 Jan; 58(1):35-44. PubMed ID: 33509441
[TBL] [Abstract][Full Text] [Related]
3. A pharmacodynamic assay to monitor treatment with the hypomethylating cytosine analogs, decitabine and azacitidine.
Jacobberger JW; Woost PG
Methods Cell Biol; 2024; 186():131-150. PubMed ID: 38705597
[TBL] [Abstract][Full Text] [Related]
4. Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.
Yoshida-Sakai N; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Kurahashi Y; Fukuda-Kurahashi Y; Kimura S
Int J Cancer; 2022 Apr; 150(7):1184-1197. PubMed ID: 34913485
[TBL] [Abstract][Full Text] [Related]
5. Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies.
Awada H; Mahfouz RZ; Kishtagari A; Kuzmanovic T; Durrani J; Kerr CM; Patel BJ; Visconte V; Radivoyevitch T; Lichtin A; Carraway HE; Maciejewski JP; Saunthararajah Y
Br J Haematol; 2020 Mar; 188(6):924-929. PubMed ID: 31736067
[TBL] [Abstract][Full Text] [Related]
6. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
[TBL] [Abstract][Full Text] [Related]
7. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
8. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
Stewart DJ; Issa JP; Kurzrock R; Nunez MI; Jelinek J; Hong D; Oki Y; Guo Z; Gupta S; Wistuba II
Clin Cancer Res; 2009 Jun; 15(11):3881-8. PubMed ID: 19470736
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Saunthararajah Y; Sekeres M; Advani A; Mahfouz R; Durkin L; Radivoyevitch T; Englehaupt R; Juersivich J; Cooper K; Husseinzadeh H; Przychodzen B; Rump M; Hobson S; Earl M; Sobecks R; Dean R; Reu F; Tiu R; Hamilton B; Copelan E; Lichtin A; Hsi E; Kalaycio M; Maciejewski J
J Clin Invest; 2015 Mar; 125(3):1043-55. PubMed ID: 25621498
[TBL] [Abstract][Full Text] [Related]
10. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4.
Vernier M; McGuirk S; Dufour CR; Wan L; Audet-Walsh E; St-Pierre J; Giguère V
Oncogene; 2020 Oct; 39(41):6406-6420. PubMed ID: 32855526
[TBL] [Abstract][Full Text] [Related]
12. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines.
Hagemann S; Heil O; Lyko F; Brueckner B
PLoS One; 2011 Mar; 6(3):e17388. PubMed ID: 21408221
[TBL] [Abstract][Full Text] [Related]
13. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal.
Ghoshal K; Datta J; Majumder S; Bai S; Kutay H; Motiwala T; Jacob ST
Mol Cell Biol; 2005 Jun; 25(11):4727-41. PubMed ID: 15899874
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.
Vijayaraghavalu S; Labhasetwar V
Cancer Lett; 2013 Apr; 331(1):122-9. PubMed ID: 23305699
[TBL] [Abstract][Full Text] [Related]
15. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
16. KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells.
Frazzi R; Cusenza VY; Pistoni M; Canovi L; Cascione L; Bertoni F; Merli F
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751409
[TBL] [Abstract][Full Text] [Related]
17. Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.
Carraway HE; Malkaram SA; Cen Y; Shatnawi A; Fan J; Ali HEA; Abd Elmageed ZY; Buttolph T; Denvir J; Primerano DA; Fandy TE
Sci Rep; 2020 Jun; 10(1):10325. PubMed ID: 32587297
[TBL] [Abstract][Full Text] [Related]
18. The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.
Yan F; Shen N; Pang J; Molina JR; Yang P; Liu S
J Biol Chem; 2015 Jul; 290(30):18480-94. PubMed ID: 26085088
[TBL] [Abstract][Full Text] [Related]
19. miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.
Mayer MC; Berg JL; Perfler B; Hatzl S; Herzog SA; Bachmaier G; Berghold A; Reinisch A; Wölfler A; Sill H; Zebisch A
Ann Hematol; 2021 Nov; 100(11):2845-2847. PubMed ID: 34291333
[No Abstract] [Full Text] [Related]
20. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Stresemann C; Lyko F
Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
